Clinical trials: Phase 1
Solid Tumor (Phase I)
A Phase I Study of ABSK211 in Participants With Advanced Solid Tumors With KRAS Alteration
This is a first-in-human (FIH), multicenter, open-label, phase I study of ABSK211 in participants with advanced solid tumors to evaluate safety, tolerability, PK and optimize the dosage.
- Trial name
- NCT07718165
- Testing
- ABSK211
- Where
- China
- Volunteers
- 247 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Nausea and Vomiting, Chemotherapy-Induced
A Study to Assess the Safety and Interaction Between Casopitant and Ketoconazole When Taken By Healthy Adults
Casopitant may affect liver enzymes that metabolize ketoconazole. This study is designed to test the safety and the extent of the Casopitant affect on ketoconazole levels in healthy human subjects.
- Trial name
- NCT00460707
- Testing
- Casopitant 150 mg, Ketoconazole, Casopitant 50 mg
- Where
- 3 sites in United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Phase 1b Influenza Vaccine Study in Healthy Subjects
The purpose of this study is to see whether a single vaccination (injection) with the investigational influenza vaccine is safe in healthy subjects.
- Trial name
- NCT01181336
- Testing
- Influenza vaccine (FLU-v), FLU-v Control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
This phase I trial is studying the side effects and best dose of RO4929097 in treating patients with recurrent invasive gliomas. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth
- Conditions
- Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01269411
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, therapeutic conventional surgery, pharmacological study
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignancies, Tumors
A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function
Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.
- Trial name
- NCT00421044
- Testing
- Patupilone/EPO906
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Huntington Disease
Optimizing Parameters of Low-Intensity Focused Ultrasound for Pallidal Modulation in Huntington's Disease
The purpose of this research study is to determine the optimal pulse repetition frequency of low-intensity focused ultrasound that is safe and effective in improving motor symptoms in patients with Huntington's disease.
- Trial name
- NCT07513844
- Testing
- Low-Intensity Focused Ultrasound Stimulation（LIFU）
- Where
- China
- Volunteers
- 24 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Leishmaniasis
Safety and Drug Absorption of Orally Administered Oleylphosphocholine (OlPC) in Healthy Adults
The goal of this interventional study is to assess the safety and tolerability of OlPC and to characterize the pharmacokinetics (PK) of OlPC following single, ascending doses administered orally in healthy-fed subjects.
- Trial name
- NCT06124144
- Testing
- Oleylphosphocholine
- Where
- Germany
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University Hospital Tuebingen
Solid Malignancy, Lymphoma
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
This is a Phase I study. This study is the first time that a new experimental drug called 18FFluoroglutamine, or F-Glutamine, is being used in people.
- Trial name
- NCT01697930
- Testing
- [18F] 4-L-Fluoroglutamine (2S,4R)
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Tumors
Study Evaluating SKI-606 in Subject With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of oral SKI-606 (100, 200, 300 or 400 mg) administered on a daily schedule to subjects with advanced malignant solid tumors and to define a maximum tolerated…
- Trial name
- NCT01001936
- Testing
- SKI-606
- Volunteers
- 28 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Ulcerative Colitis
GI-270384 Study In Patients With Mild To Moderate Ulcerative Colitis
The aim of this double blind, placebo controlled, study is to evaluate activity consistent with efficacy provided by 14 days administration of GI270384X, and to provide preliminary pharmacokinetics and safety/tolerability of 14…
- Trial name
- NCT00457171
- Testing
- GI-270384
- Volunteers
- 16 people
- Sponsor
- GlaxoSmithKline
Tumors
Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.
- Trial name
- NCT00339144
- Testing
- Dasatinib
- Where
- 2 sites in Japan
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Healthy
A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants
The purpose of Part 1 of this study is to assess the safety and tolerability of 2 dose levels (1.4 and 2.8 mg/kg) of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328.
- Trial name
- NCT02074800
- Testing
- CNTO 328 (Sp2/0-derived), CNTO 328 (CHO-derived)
- Where
- 2 sites in United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Centocor, Inc.
Neoplasms
BAY80-6946 Open Label, Phase I Study in Patients With Advanced Cancer
The purpose of this study is to determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
- Trial name
- NCT00962611
- Testing
- Copanlisib (Aliqopa, BAY80-6946)
- Where
- 3 sites in United States
- Volunteers
- 57 people
- Sponsor
- Bayer
Neoplasms
A Study of ADH-1 in Combination With Normothermic Isolated Limb Infusion of Melphalan
N-cadherin, a protein involved in blood vessel cell binding and on the surface of many tumor cells, is increased as cancer progresses. ADH-1 blocks N-cadherin.
- Trial name
- NCT00421811
- Testing
- ADH-1, melphalan
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Adherex Technologies, Inc.
Soft Tissue Sarcomas
Phase I Study of Safety and Feasibility of Transarterial Embolization of Incurable Hypervascular Pediatric Soft Tissue Sarcomas
This is a single center, single arm phase I clinical trial exploring the feasibility and safety of performing transarterial embolization of incurable hypervascular pediatric soft tissue sarcomas with at least an index tumor with…
- Trial name
- NCT07136571
- Testing
- bland particles
- Sponsor
- University of Alabama at Birmingham
Non-Secretory Plasma Cell Myeloma, Plasmacytosis
Panobinostat and Carfilzomib in Treating Participants With Relapsed or Refractory Multiple Myeloma
This phase I/Ib trial studies the side effects and best dose of panobinostat and carfilzomib in treating participants with multiple myeloma that has come back or that isn't responding to treatment.
- Conditions
- Non-Secretory Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Trial name
- NCT01301807
- Testing
- Carfilzomib, Panobinostat
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- M.D. Anderson Cancer Center
Healthy Male Subjects
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
This study will assess the effects of strong CYP1A2 (Cytochrome P450 1A2) inhibitor (fluvoxamine) on savolitinib exposure in healthy male subjects, performed at a single clinical unit.
- Trial name
- NCT05888207
- Testing
- Savolitinib, Fluvoxamine
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Urinary Bladder Neoplasms
A Study of Stimulator of Interferon Genes (STING) Agonist E7766 in Non-muscle Invasive Bladder Cancer (NMIBC) Including Participants Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy, INPUT-102
This is an open label, multicenter, phase 1/1b study to assess safety/tolerability and preliminary clinical activity of E7766 as a single agent administered intravesically in participants with NMIBC.
- Trial name
- NCT04109092
- Testing
- E7766
- Where
- 9 sites in United States
- Sponsor
- Eisai Inc.
FIGO Stage IIC-IV Ovarian Carcinoma, Fallopian Tube Carcinoma
Heated Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Peritoneal Cancer
This phase I trial studies the side effects and best dose of heated carboplatin given into the abdomen at the time of surgery in treating patients with stage II-IV ovarian, fallopian tube, or peritoneal cancer.
- Conditions
- FIGO Stage IIC-IV Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma
- Trial name
- NCT02199171
- Testing
- carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Irvine
Schizophrenia
Study to Determine the Pharmacokinetics, Safety & Tolerability of Aripiprazole in Adults With Schizophrenia
This trial will determine the Pharmacokinetics, safety and tolerability of single-dose Aripiprazole administered intramuscularly in adults with schizophrenia
- Trial name
- NCT03150771
- Testing
- Aripiprazole
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.